How often it happens The rates vary by trial and population: 2,3 TRIUMPH-4 (obesity with knee osteoarthritis): 8.8% on 9 mg, 20.9% on 12 mg, 0.7% on placebo TRANSCEND-T2D-1 (type 2 diabetes): 4.5% on 4 mg, 2.3% on 9 mg, 4.4% on 12 mg, 0% on placebo Phase 2 trial (Jastreboff 2023): not reported The TRIUMPH-4 numbers are markedly higher than those of TRANSCEND-T2D-1
First-line management includes drinking 1.52 litres of fluids daily, using paracetamol (maximum 4 g daily) or ibuprofen (maximum 1.2 g daily for over-the-counter use) as appropriate, and resting in a quiet environment
The Next Wave of GLP-1 Options: Bigger, Better, and More Powerful A new generation of GLP-1 therapies is on the horizon, and they may be even more effective for both blood sugar and weight management
Foundayo (Orforglipron) Foundayo, approved in April 2026, is a GLP-1 medication available as a once-daily pill
RxPepsDirect prescribes BPC-157 in the 28 states its medical team is licensed in
The majority of adults were prescribed their first GLP-1 receptor agonist in 2017 or 2018